Tags : Kiniksa

Weekly Snapshot

PharmaShots Weekly Snapshots (Mar 15 – 19, 2021)

Takeda Collaborates with Anima to Discover and Develop mRNA Translation Modulators for Neurological Diseases Published: Mar 19, 2021 | Tags: Takeda, Collaborates, Anima, Discover, Develop, mRNA Translation Modulators, Neurological Diseases Kiniksa’s Arcalyst (rilonacept) Receives the US FDA’s Approval for the Treatment of Pericarditis Published: Mar 19, 2021 | Tags: Kiniksa, Arcalyst (rilonacept), Receives, US, FDA, […]Read More

Insights+

Insights+: Breakthrough Therapy Designation by the US FDA in 2020

Breakthrough Therapy (BT) Designation is an expedited review program introduced in Section 902 of the Food and Drug Safety and Innovation Act of 2012 The Breakthrough Designation is granted to the drug candidates as monotherapy or in combination with other drugs intended to treat serious or life-threatening diseases and has shown substantial improvement over available […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (December 09-13, 2019)

1.  Pfizer’s Amsparity (biosimilar, adalimumab) Receives CHMP’s Positive Opinion for Inflammatory and Autoimmune Disorders Published: Dec 12, 2019 | Tags: Pfizer, Amsparity, biosimilar, adalimumab, Receives, CHMP, Positive Opinion, Inflammatory, Autoimmune Disorders 2.  Janssen’s Darzalex (daratumumab) Combination Regimen Receives CHMP’s Positive Opinion for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma Published: Dec 13, 2019 | […]Read More

Pharma

Kite and Kiniksa Collaborate to Evaluate the Combination of Yescarta

Shots: Kite and Kiniksa enter into a clinical collaboration to conduct a P-II study assessing Yescarta + mavrilimumab in patients with r/r LBCL. Kite will sponsor and conduct the study The P-II study will determine the effect of GM-CSFRα inhibition with mavrilimumab on the clinical safety of Yescarta. The collaboration supports Kiniksa’s objective to develop […]Read More